SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease
- PMID: 31234232
- PMCID: PMC7322732
- DOI: 10.1002/mds.27770
SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease
Abstract
Background: Single nucleotide polymorphisms (SNPs) in the α-synuclein (SNCA) gene are associated with differential risk and age at onset (AAO) of both idiopathic and Leucine-rich repeat kinase 2 (LRRK2)-associated Parkinson's disease (PD). Yet potential combinatory or synergistic effects among several modulatory SNPs for PD risk or AAO remain largely underexplored.
Objectives: The mechanistic target of rapamycin (mTOR) signaling pathway is functionally impaired in PD. Here we explored whether SNPs in the mTOR pathway, alone or by epistatic interaction with known susceptibility factors, can modulate PD risk and AAO.
Methods: Based on functional relevance, we selected a total of 64 SNPs mapping to a total of 57 genes from the mTOR pathway and genotyped a discovery series cohort encompassing 898 PD patients and 921 controls. As a replication series, we screened 4170 PD and 3014 controls available from the International Parkinson's Disease Genomics Consortium.
Results: In the discovery series cohort, we found a 4-loci interaction involving STK11 rs8111699, FCHSD1 rs456998, GSK3B rs1732170, and SNCA rs356219, which was associated with an increased risk of PD (odds ratio = 2.59, P < .001). In addition, we also found a 3-loci epistatic combination of RPTOR rs11868112 and RPS6KA2 rs6456121 with SNCA rs356219, which was associated (odds ratio = 2.89; P < .0001) with differential AAO. The latter was further validated (odds ratio = 1.56; P = 0.046-0.047) in the International Parkinson's Disease Genomics Consortium cohort.
Conclusions: These findings indicate that genetic variability in the mTOR pathway contributes to SNCA effects in a nonlinear epistatic manner to modulate differential AAO in PD, unraveling the contribution of this cascade in the pathogenesis of the disease. © 2019 International Parkinson and Movement Disorder Society.
Keywords: Parkinson's disease; SNP; age at onset; alpha-synuclein; epistasis; mTOR.
© 2019 International Parkinson and Movement Disorder Society.
Conflict of interest statement
Similar articles
-
MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson's Disease Patients.Mol Neurobiol. 2019 Mar;56(3):2092-2100. doi: 10.1007/s12035-018-1219-1. Epub 2018 Jul 10. Mol Neurobiol. 2019. PMID: 29992529
-
SNCA but not DNM3 and GAK modifies age at onset of LRRK2-related Parkinson's disease in Chinese population.J Neurol. 2019 Jul;266(7):1796-1800. doi: 10.1007/s00415-019-09336-7. Epub 2019 Apr 30. J Neurol. 2019. PMID: 31041581
-
Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility?Parkinsonism Relat Disord. 2011 Dec;17(10):730-6. doi: 10.1016/j.parkreldis.2011.07.001. Epub 2011 Aug 3. Parkinsonism Relat Disord. 2011. PMID: 21816655 Free PMC article.
-
Association between alpha-synuclein (SNCA) rs11931074 variability and susceptibility to Parkinson's disease: an updated meta-analysis of 41,811 patients.Neurol Sci. 2020 Feb;41(2):271-280. doi: 10.1007/s10072-019-04107-8. Epub 2019 Nov 22. Neurol Sci. 2020. PMID: 31758346 Review.
-
Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review.Mov Disord. 2018 Dec;33(12):1857-1870. doi: 10.1002/mds.27527. Epub 2018 Oct 24. Mov Disord. 2018. PMID: 30357936
Cited by
-
Platelet miRNA Biosignature Discriminates between Dementia with Lewy Bodies and Alzheimer's Disease.Biomedicines. 2021 Sep 20;9(9):1272. doi: 10.3390/biomedicines9091272. Biomedicines. 2021. PMID: 34572457 Free PMC article.
-
Mitochondria-lysosome crosstalk in GBA1-associated Parkinson's disease.3 Biotech. 2022 Sep;12(9):230. doi: 10.1007/s13205-022-03261-9. Epub 2022 Aug 18. 3 Biotech. 2022. PMID: 35992895 Free PMC article. Review.
-
Scrutinizing neurodegenerative diseases: decoding the complex genetic architectures through a multi-omics lens.Hum Genomics. 2024 Dec 31;18(1):141. doi: 10.1186/s40246-024-00704-7. Hum Genomics. 2024. PMID: 39736681 Free PMC article. Review.
-
α-Synuclein Gene Hypomethylation in LRRK2 Parkinson's Disease Patients.Mov Disord. 2025 Mar;40(3):550-555. doi: 10.1002/mds.30094. Epub 2024 Dec 23. Mov Disord. 2025. PMID: 39711195 Free PMC article.
-
A systematic review of associations between common SNCA variants and clinical heterogeneity in Parkinson's disease.NPJ Parkinsons Dis. 2021 Jul 1;7(1):54. doi: 10.1038/s41531-021-00196-5. NPJ Parkinsons Dis. 2021. PMID: 34210990 Free PMC article. Review.
References
-
- Fahn S Medical treatment of Parkinson’s disease. J Neurol 1998; 245(11 suppl 3):P15–P24. - PubMed
-
- Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron 2003;39(6):889–909. - PubMed
-
- Marras C, Lang A, van de Warrenburg BP, Sue CM, Tabrizi SJ, Bertram L, et al. Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force. Mov Disord 2017;32(5):724–725. - PubMed
-
- Pont-Sunyer C, Hotter A, Gaig C, Seppi K, Compta Y, Katzenschlager R, et al. The Onset of Nonmotor Symptoms in Parkinson’s disease (The ONSET PDStudy). Mov Disord 2015;30(2):229–237. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous